Aktis Oncology, Inc. (AKTS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$15.20+1.74%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · AKTS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -58.9% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 206 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 87.4% |
Growth built into the price is above our model estimate.
The price assumes 146.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
AKTS — earnings in line
Dated 2026-08-13
of this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
Why it matters: The trial would test AKY-2519 in lung and other B7-H3 tumors. A delay would push back a key pipeline step.
Supportive ifAktis announces that the Phase 1b BActinium-2 trial has started in lung or other B7-H3 tumors by December 31, 2026.
Worry ifAktis reports that the trial has not started by December 31, 2026, or gives a later start date.
Why it matters: These data will give an early read on AKY-1189 in Nectin-4 tumors. Safety and tumor response results can support or weaken its promise.
Watch forAktis reports early Phase 1b data in Q1 2027. The data show tumor activity, with no new safety concern.
Also watch forThe data show no tumor activity, a serious safety concern, or a delay beyond Q1 2027.
Why it matters: The results will test AKY-2519 in prostate cancer patients, including those treated with PLUVICTO. Clear tumor activity would support further study.
Watch forAktis reports 2027 trial data that show tumor activity in mCRPC patients. No serious safety issue is noted.
Also watch forThe data show no tumor activity, a serious safety issue, or a delay beyond 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$229 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $623 loss on $10,000 · 6.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,473 loss on $10,000 · 54.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.